... Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation / attempts and / or concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS-depressant drugs. Do not prescribe propoxyphene for patients who are suicidal or have a history of suicidal ideation. · The metabolism of propoxyphene may be altered by strong CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazadone, amiodarone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) leading to enhanced propoxyphene plasma levels. Patients receiving propoxyphene and any CYP3A4 inhibitor should be carefully monitored for an extended period of time and dosage adjustments should be made if warranted (see CLINICAL PHARMACOLOGY ­ Drug Interactions, WARNINGS, PRECAUTIONS and DOSAGE AND ADMINISTRATION for further information). DESCRIPTION Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is ...

... reduction in active metabolite levels of about 45 %was found in people who received clopidogrel with omeprazole compared to those taking clopidogrel alone. The effect of clopidogrel on platelets was reduced by as much as 47 %in people receiving clopidogrel and omeprazole together. These reductions were seen whether the drugs were given at the same time or 12 hours apart. Other drugs that are potent inhibitors of the CYP 2C19 enzyme would be expected to have a similar effect and should be avoided in combination with clopidogrel. These include: cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine, and ticlopidine. Since the level of inhibition among other PPIs varies, it is unknown to what amount other PPIs may interfere with clopidogrel. However, esomeprazole, a PPI that is a component of omeprazole, inhibits CYP2C19 and should also be avoided in combination with clopidogrel. FDA is aware there are studies, such as the Clopidogrel and Optimization of Gastrointestinal Events (COGENT) study, that might provide information about the effect of this interaction on clinical outcome. Although the ...

... mg) resulted in no change in plasma concentrations of rosuvastatin. Erythromycin: Coadministration of erythromycin (500 mg four times daily for 7 days) with rosuvastatin (80 mg) decreased AUC and Cmax of rosuvastatin by 20 %and 31 %, respectively. These reductions are not considered clinically significant. Itraconazole: Itraconazole (200 mg once daily for 5 days) resulted in a 39 %and 28 %increase in AUC of rosuvastatin after 10 mg and 80 mg dosing, respectively. These increases are not considered clinically significant. Fluconazole: Coadministration of fluconazole (200 mg once daily for 11 days) with rosuvastatin (80 mg) resulted in a 14 %increase in AUC of rosuvastatin. This increase is not considered clinically significant. Cyclosporine: Coadministration of cyclosporine with rosuvastatin resulted in no significant changes in cyclosporine plasma concentrations. However, Cmax and AUC of rosuvastatin increased 11-and 7-fold, respectively, compared with historical data in healthy subjects. These increases are considered to be clinically significant (see PRECAUTIONS, Drug Interactions, WARNINGS, Myopathy / Rhabdomyolysis, and DOSAGE ...

... Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation / attempts and / or concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS-depressant drugs. Do not prescribe propoxyphene for patients who are suicidal or have a history of suicidal ideation. · The metabolism of propoxyphene may be altered by strong CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazadone, amiodarone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) leading to enhanced propoxyphene plasma levels. Patients receiving propoxyphene and any CYP3A4 inhibitor should be carefully monitored for an extended period of time and dosage adjustments should be made if warranted (see CLINICAL PHARMACOLOGY ­ Drug Interactions, WARNINGS, PRECAUTIONS and DOSAGE AND ADMINISTRATION for further information). DESCRIPTION Propoxyphene Napsylate, USP is an odorless, white crystalline powder with a bitter taste. It is very slightly soluble in water and soluble in methanol, ethanol, chloroform, and acetone. Chemically, it is ...

... across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues. Metabolism Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients. In vitro studies using human liver microsomes indicate that cytochromes P450 3A4 and 2C9 are involved in the metabolism of montelukast. Clinical studies investigating the effect of known inhibitors of cytochromes P450 3A4 (e.g, ketoconazole, erythromycin) or 2C9 (e.g, fluconazole) on montelukast pharmacokinetics have not been conducted. Based on further in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 (see Drug Interactions). In vitro studies have shown that montelukast is a potent inhibitor of cytochrome P450 2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) 2 XXXXXXX SINGULAIR ® (Montelukast Sodium) Tablets, Chewable Tablets ...

... 0.7 %of these cases, the events occurred in the absence of identified risk factors: in the remaining cases, risk factor status was unknown. Because the cases were reported voluntarily from a population of unknown size, estimates of adverse events frequency cannot be made (See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and Drug Interactions) Numerous drug classes and agents increase the risk of developing serious cardiac arrhythmias. PROPULSID is contraindicated in patients taking certain macrolide antibiotics (such as clarithromycin, erythromycin, and troleandomycin ), certain antifungals (such as fluconazole, itraconazole, and ketoconazole ), protease inhibitors (such as indinavir and ritonavir ), phenothiazines (such as prochlorperazine and promethazine ); Class IA and Class III antiarrhythmics (such as quinidine, procainamide, and sotalol ); tricylic antidepressants (such as amitriptyline ); certain antidepressants (such as nefazodone and maprotiline ); certain antipsycotic medications (such as sertindole) as well as other agents (such as bepridil, sparfloxacin, and grapefruit juice). See PRECAUTIONS: Drug Interactions) The preceding list is not comprehensive. QT prolongation, torsades de pointes (sometimes ...

... patient should not swallow ELIDEL Cream and should contact the physician if they do. Drug Interactions Potential interactions between ELIDEL and other drugs, including immunizations, have not been systematically evaluated. Due to low blood levels of pimecrolimus detected in some patients after topical application, systemic drug interactions are not expected, but cannot be ruled out. The concomitant administration of known CYP3A family of inhibitors in patients with widespread and / or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine. Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year rat dermal carcinogenicity study using ELIDEL Cream, a statistically significant increase in the incidence of follicular cell adenoma of the thyroid was noted in low, mid and high dose male animals compared to vehicle and saline control male animals. Follicular cell adenoma of the thyroid was noted in the dermal rat carcinogenicity study at the lowest dose of 2 mg / kg / day [0.2 %pimecrolimus cream; 1.5X the Maximum Recommended Human Dose (MRHD) based on ...

... Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)-December 2008 The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT / MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. Summary View Sections Modified DRUG INTERACTIONS (7.6) Amiodarone (new) The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with Coreg may enhance the Î ²-blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of bradycardia or heart block, particularly when one agent is added to pre-existing treatment with the other.-- Links on this page: Page Last Updated: 06 / 19 / 2009 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Home About FDA Contact Us A to Z Subject Index Site Map Web Site Policies FOIA Accessibility ...

... Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)-December 2008 The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT / MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. Summary View Sections Modified DRUG INTERACTIONS (7.6) Amiodarone (new) The concomitant administration of amiodarone or other CYP2C9 inhibitors such as fluconazole with Coreg may enhance the Î ²-blocking properties of carvedilol resulting in further slowing of the heart rate or cardiac conduction. Patients should be observed for signs of bradycardia or heart block, particularly when one agent is added to pre-existing treatment with the other.-- Links on this page: Page Last Updated: 06 / 19 / 2009 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Home About FDA Contact Us A to Z Subject Index Site Map Web Site Policies FOIA Accessibility ...

... release tablets Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) â €“ March 2010 Summary View PRECAUTIONS Use in Cirrhotic Patients Use in Cirrhotic patients: Clearance of nifedipine is reduced and systemic exposure increased in patients with cirrhosis. It is unknown how systemic exposure may be altered in patients with moderate to severe liver impairment. Careful monitoring and dose reduction may be necessary; consider initiating therapy with the lowest dose available. Drug Interactions CYP 3A inhibitors: CYP 3A inhibitors such as ketoconazole fluconazole, itraconazole clarithromycin, erythromycin, grapefruit, nefazodone, saquinar, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. Careful monitoring and dose adjustment may be necessary; consider initiating nifedipine at the lowest dose available if given concomitantly with these medications. Strong CYP3A Inducers, such as rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, and St. Johnâ €™ s Wort Antitubercular Drugs: Strong CYP 3A inducers, such as rifampin, rifapentin, and rifabutin reduce the bioavailability of nifedipine which will reduce the efficacy ...